Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Sky One Has Another 26 Products Awaiting Approval

publication date: Sep 10, 2008

China Sky One Medical, with its near-constant barrage of press releases, sometimes seems like an overactive child who always demands attention. On the other hand, the company’s insistent press release schedule is understandable because the company is growing rapidly, its finances are in good order, but investors don’t seem to be paying attention. Today, the company announced that its Heilongjiang Tianlong Pharmaceutical subsidiary has completed its R&D on 26 new drugs and submitted the drugs to the SFDA for approval. More details...

Stock Symbol: (AMEX: CSY)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital